DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Demetri GD, Reichardt P, Kang YK et al.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Lancet 2013;
381: 295-302
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.